$SLP News

Simulations Plus, Inc. 2026 Q3 - Results - Earnings Call Presentation

Simulations Plus Affirms FY2026 Adj EPS Guidance of $0.75-$0.85 vs $0.42 Est; Affirms FY2026 Sales Guidance of $79.000M-$82.000M vs $81.598M Est

Simulations Plus (NASDAQ:SLP) Beats Q3 Estimates by Wide Margin but Shares Edge Lower on Profit-Taking

Simulations Plus Q3 Adj. EPS $0.30 Beats $0.13 Estimate, Sales $21.886M Beat $20.918M Estimate

Simulations Plus Announces Altaris To Pay $26M If Proposed Merger Plan Terminated

William Blair Downgrades Simulations Plus to Market Perform

Simulations Plus Agrees To Be Acquired By Altaris For $18.50/Share

Is It Too Late To Consider Buying Simulations Plus, Inc. (NASDAQ:SLP)?

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

This Analyst Just Made A Huge Upgrade To Their SLP Resources Berhad (KLSE:SLP) Earnings Forecasts

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Do Options Traders Know Something About Simulations Plus Stock We Don't?

Biosimulation Market Research and Global Forecast Report 2026-2036: Expansion Driven by Precision Medicine, AI-Powered In-Silico Drug Development and Rising Demand for Cost-Efficient Clinical Trials

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Partners With Lonza Group, FDA To Develop, Validate Framework For Amorphous SOLID Dispersion Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development

How The Sylvania Platinum (AIM:SLP) Story Is Shifting As Valuation Tweaks Meet New Guidance

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus Q2 Earnings Call Highlights